FNY Investment Advisers’s INmune Bio INMB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-100
Closed -$1 602
2024
Q1
$1 Hold
100
﹤0.01% 623
2023
Q4
$1K Buy
+100
New +$838 ﹤0.01% 426
2023
Q3
Sell
-100
Closed 668
2023
Q2
$0 Hold
100
﹤0.01% 609
2023
Q1
$0 Hold
100
﹤0.01% 642
2022
Q4
$0 Sell
100
-150
-60% -$1.06K ﹤0.01% 599
2022
Q3
$1K Hold
250
﹤0.01% 584
2022
Q2
$2K Sell
250
-250
-50% -$1.86K ﹤0.01% 577
2022
Q1
$4K Sell
500
-600
-55% -$5.39K ﹤0.01% 551
2021
Q4
$11K Buy
1,100
+300
+38% +$4.44K 0.01% 381
2021
Q3
$15K Buy
800
+500
+167% +$9.65K 0.01% 506
2021
Q2
$5K Sell
300
-5,900
-95% -$79.5K ﹤0.01% 629
2021
Q1
$73K Buy
6,200
+1,800
+41% +$32.4K 0.03% 374
2020
Q4
$75K Buy
4,400
+800
+22% +$7.53K 0.02% 321
2020
Q3
$37K Buy
3,600
+2,600
+260% +$26.5K 0.02% 262
2020
Q2
$5K Buy
+1,000
New +$5.04K ﹤0.01% 324
2019
Q2
Sell
-200
Closed -$1K 1055
2019
Q1
$1K Buy
+200
New +$1.55K ﹤0.01% 651

Other funds holding INMB

FNY Investment Advisers's INMB Position: Q2 2024 in Review

FNY Investment Advisers sold out of INmune Bio (INMB) in Q2 2024, closing a stake of 100 shares — an estimated $1 sold.

FNY Investment Advisers first reported a position in INMB in Q1 2019 and held it in 16 quarters. The position peaked at $75K in Q4 2020. 57 funds tracked by Wall St. Rank hold INMB as of Q2 2024.

  • FNY Investment Advisers reported no remaining INmune Bio position as of Q2 2024 after selling out during the quarter.
  • FNY Investment Advisers sold 100 INmune Bio shares in Q2 2024, an estimated $1.
  • FNY Investment Advisers first reported a position in INmune Bio in Q1 2019 and held it in 16 quarters.
  • FNY Investment Advisers's INmune Bio position peaked at $75K in Q4 2020.
  • 57 funds tracked by Wall St. Rank held INmune Bio as of Q2 2024.

Based on FNY Investment Advisers's 13F filing for Q2 2024, filed 5 Aug 2024.